Papers/PMID:34556670
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.
Nature communications2021The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
berberine — no detected effect on fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Notably, compared with the placebo, BBR did not change fasting blood glucose (FBG), fasting insulin or fasting proinsulin C-peptide levels (Supplementary Table 2).”
Quoted verbatim from Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.. - Study
- crossover
- Participants
- 15
- Dose
- single oral dose of 1 g berberine tablets
- Population
- 15 healthy men with normal glucose tolerance; secondary observation in a single-dose hyperglycaemic clamp trial, fasting glucose measured after an overnight fast before and after dosing
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.2021PMID:34556670Permalink